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Diabetic nephropathy (DN) is a serious complication of diabetes. At its core, DN is a metabolic disorder which can also manifest
itself in terms of local inflammation in the kidneys. Such inflammation can then drive the classical markers of fibrosis and structural
remodeling. As a result, resolution of immune-mediated inflammation is critical towards achieving a cure for DN. Many immune
cells play a part in DN, including key members of both the innate and adaptive immune systems. While these cells were classically
understood to primarily function against pathogen insult, it has also become increasingly clear that they also serve a major role as
internal sensors of damage. In fact, damage sensing may serve as the impetus for much of the inflammation that occurs in DN, in
a vicious positive feedback cycle. Although direct targeting of these proinflammatory cells may be difficult, new approaches that
focus on their metabolic profiles may be able to alleviate DN significantly, especially since dysregulation of the local metabolic
environment may well be responsible for triggering inflammation to begin with. In this review, the authors consider the metabolic
profile of several relevant immune types and discuss their respective roles.
1. Introduction
Diabetic nephropathy (DN) is the most common complica-
tion and leading cause of mortality associated with diabetes
[1]. DN is a leading contributor to cases of kidney failure
in developed countries, and both type I and type II forms
of diabetes can result in DN [2]. While the global pattern
of DN incidence is not fully surveyed, it is nonetheless a
widespread occurrence presently that is expected to increase
in prevalence [3]. Numerous factors, both environmental
and genetic, have been reported to influence DN onset,
severity, and the rate of progression. DN is assessed clinically
through a five-stage system of criteria, with each stage
featuring a distinct set of functional and structural changes
and reflected alterations in benchmark renal function mark-
ers [4]. The structural changes begin with glomerular and
tubular hypertrophy and the thickening of the basement
membrane and mesangium expansion, leading to end-stage
glomerular closure and tubulointerstitial fibrosis [5, 6].These
changes are driven primarily by the dysregulation of typical
glucose metabolism pathways, leading to the characteristic
loss of blood glucose control and aberrant adipose function
[7–9]. This loss of glucose control can lead to a number of
other changes, including inflammation and cellular stress.
While perhaps not as dramatically observed as in
some other conditions, inflammatory processes are heavily
involved in the structural deterioration that occurs in DN.
This involvement is only natural given that inflammation
is known to be involved in the pathogenesis of diabetes,
with elevation of serum inflammation markers in long term
diabetes patients [10].The cause(s) of inflammation inDNare
not clear, but some combination of pathogen insult and/or
tissue damage may be responsible. The former is not likely
to be the strongest contributor however, as the kidney is not
typically exposed to pathogens and has not been shown to
be more vulnerable during DN. Since it is very likely that
the inflammation occurring in DN is sterile and chronic,
intrinsic kidney cell injury, namely, injury to glomerular,
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tubular, and vascular cells, may be the main cause. Damage
or danger signals released by injured renal cells can trigger
remodeling processes by stimulating renal cells and activating
immune cells of both the innate and adaptive systems. Other
metabolic signals may also contribute. In this review, the
authors will review the roles played by, and crosstalk between,
several T cells,macrophages, dendritic cells, and renal tubular
cells, which are among the most important cell types con-
tributing to the inflammation mediated acceleration of DN
progression. The authors will consider the impact glucose
metabolism and other mechanisms of metabolic control may
have on these different cell types as a key explanatory factor
for DN pathogenesis.
2. Antigen Presenting Cells
Dendritic cells are the professional APCs in the body, and
their function is intimately tied to the progression of diabetic
nephropathy.DCs exist primarily in two types: themore com-
mon myeloid-derived type (mDC) and the less common, but
more highly pathogenic, plasmacytotic (pDC) variety. mDCs
and pDCs differ primarily in terms of TNF𝛼 production, with
the high levels of TNF𝛼 secreted by pDCs having been shown
to result in significant morphological changes in DN as well
as other autoimmune and inflammatory disorders [11]. More
importantly however, DCs can act as keen sensors of damage,
being armed with a complete repertoire of receptors for both
extrinsic pathogens and intrinsic factors. These include most
classes of pattern-recognition receptors, including Toll-like
receptors, NOD-like receptors, and C-type lectin receptors,
which may also coligate [12]. Following activation by these
stimuli, DCs can begin initiating an inflammatory response
to counter a perceived threat, potentially via NLRP3 or alter-
native “licensing” [13, 14]. DC linkage with T cells is sufficient
to activate the T cell receptor (TCR) and drive adaptive
responses. Signaling along these complex pathways generally
ends in the activation of transcription factors such as IRF7,
NF-𝜅B, and IRAK, which can then coordinate the secretion
of varied chemokines to attract PMNs and alter the behavior
of other nearby cells [15, 16]. DCs are able to sense extracel-
lularly through cell surface receptors and intracellularly via
endosome-surface receptors. These latter receptors, such as
TLR8, may also permit DCs to directly sense microRNAs
and other molecules taken up as exosomes [17]. Overall,
DC phagocytosis and the ensuing processing mechanisms
are critical to the initiation of inflammation. DCs are widely
present in the renal tubulointerstitium in normal mice,
and immunohistochemistry has also revealed the significant
numbers of bothmDCs and pDCs in normal human kidneys.
As such, resident DCs in kidney may be readily capable of
processing damaged cells and signals and consequently initi-
ate the cycle of tissue damage and repair present in DN. DCs
have been shown to be critically involved in tubulointerstitial
inflammation in various progressive nephritic diseases and
in the remnant kidney model. Unfortunately however, the
role for DCs in DN inflammation has not been well studied,
in part due to difficulties associated with plasticity and the
relative instability of cultured DC cell lines [18].
Similar to DCs, macrophages also function as APCs,
but few resident macrophages are normally present in the
kidneys. Curiously however, a heavily increased macrophage
presence is observed in both the glomeruli and tubulointersti-
tium in human T2D, and the prevention of such macrophage
infiltration has been the focus of some recent work [19–21].
Such an increase in the macrophage population has been
correlated with the degree of glomerulosclerosis, increased
proteinuria, increased serum creatinine levels, and the pres-
ence of interstitial fibrosis. Importantly, deletion or inhibition
of macrophage accumulation by decreasing intracellular
adhesion molecule 1, monocyte chemoattractant protein 1, or
colony-stimulating factor receptor 1 ameliorated DN in both
db/db and STZ-induced diabetic mice [22]. Given that these
knockouts primarily affect chemotaxis and late polarization,
it stands to reason that the increase in macrophages around
the kidney in DN is primarily a result of outside recruitment,
and not simply a local population expansion. Similarly,
Smad7 deletion, which impacts the TGF𝛽 signaling pathway,
has been shown to enhance macrophage recruitment to the
kidneys [23]. Since outside recruitment typically only occurs
in response to damage sensing, it can thus be expected that
these macrophages only come into play some time after the
initial damage event(s).
Two main types of macrophages, the classically activated
and proinflammatory M1 and the alternatively activated
and anti-inflammatory M2, are commonly recognized, with
the M2 type being further divided into three subtypes.
Macrophage populations are generally highly plastic how-
ever, such that rigid/exclusive production and expression
patterns are rarely observed [24]. Several authors have also
suggested various other unique macrophage populations,
based on factors such as the differential expression of Lyc6
[25]. Tissue-residentmacrophagesmay also generally express
other markers that are tissue-specific, unlike classical bone-
marrow derived macrophages [26–28]. Nonetheless, the sim-
ple classification scheme is useful for understanding many
basic aspects of macrophage function. Transitions along the
spectrum from the two extremes have been an area of particu-
lar focus and are also highly relevant to the progression ofDN.
Many of the infiltrating macrophages in the middle stages
of DN are likely to adopt the M1 type and cause significant
damage that accelerates the condition, although the precise
origin of these macrophages is not fully clear.
Many inducers of M1 activity and M1 signature products
have been implicated with DN, with TNF𝛼 being perhaps
the most notable. TNF𝛼 signaling induces production of NF-
𝜅B along a JAK/STAT pathway, leading to inflammation.
The cytosolic adaptor protein Myd88 conducts the classical
pathway for M1 function downstream of TLR signaling.
Myd88 may activate various members of the TRAF family,
leading to further activation of IRAK as well as IRF7. M1 may
also be stimulated via induction of other pattern-recognizing
receptors such as NLRs. Regardless of the precise channel
used, M1 can be stimulated by both classical pathogen-
associated molecular patterns (PAMPs), such as lipopolysac-
charide (LPS), and damage-associated molecular patterns
(DAMPs) such as extracellular DNA [29]. These stimuli may
also elicit different responses in chronic inflammation [30].
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The relevance of PAMP-driven signaling to DN mainly lies
in possible changes in response to secondary infection, a
situation that is not wholly clear. Given the known damage
and ECM changes that occur in DN however, it seems that
DAMPs are equally important to consider, if not more so.
The transcription factor IRF5 is intimately involved inM1
processes, such that IRF5 is also considered to be one of the
defining characteristics of theM1 phenotype [31]. IRF5 is also
critical for M1 production of type one interferons and also
influences the activity of iNOS, a primary means by which
M1 can generate ROS [32]. These signaling molecules work
in concert to prevent wound healing but may also prevent
hyperresponse via inhibition of other proinflammatory cell
types. After all, ROS production has been shown to lead to
the inhibition of several T effector subtypes, among others
[33]. Despite being proinflammatory, M1 are also sensitive
to oxidative stress. M1 are suppressed by an overabundance
of NO via the nitration and subsequent loss of function
of IRF5 and are actually more abundant in iNOS deficient
mice as a consequence [34]. Similarly, hypoxia has been
shown to inhibit M1 polarization via altered expression of
HIF-1𝛼 [35]. Oxidative stress has been shown to lead to
changes in autophagy and othermacrophage activities aswell.
Interestingly however, high levels of oxidative stress observed
in DN have been previously shown to result in tubular cell
and podocyte injury, and the debris from cells killed in such
mannermay also serve to further stimulateM1 and overcome
the inhibitory pressure M1 may experience otherwise.
M1 may also produce sizeable amounts of IL-6, but the
precise importance of this production is unclear given the
fact that many other cell types also secrete the cytokine
during inflammation.M1macrophages can also form inflam-
masomes to further their function, with the NLRP3 and
AIM2 varieties being the ones best characterized thus far.
These inflammasomes may form under a wide variety of
stimuli and gather together large amounts of caspase 1, which
can then cleave and activate interleukins 1beta, 18, and 33
[36]. CARD and PYR domains on these inflammasomes may
recruit and involve a broad assortment of different proteins
to further M1 function. Damage sensing by M1 macrophages
has been demonstrated to contribute to such inflammasome
activation, although the exact molecular machinery may be
varied and has not been completely characterized [37]. The
precise duration of inflammasome activation is also not well
understood.
Metabolic control of M1 has become subject of increasing
interest and may be particularly relevant to DN given the
metabolic disruption that is implicit in the condition. Recent
work has shown that M1 macrophages may have an altered
expression of the Krebs cycle enzyme isocitrate dehydroge-
nase, making it a possible target [38]. This altered expression
mayhave important ramifications given the change in glucose
availability present in DN. The glucose and salt sensor
aldose reductase has also been shown to play a key role
in M1 metabolic control, although it is not fully clear if its
control is mostly mediated by its production of sorbitol or
through other protein interactions [39]. High salt has been
demonstrated to result in increased inflammasome activity,
but it is not clear if the response is to the salt itself or just to
osmolality increase [40]. Advanced glycation end products,
commonly observed in diabetes, can also strongly influence
M1 macrophage function [41]. It is clear, however, that the
provision of high amounts of glucose is a facilitator for M1
stimulation, partly mediated through the increased expres-
sion of SREBP1 [42]. These changes may in part be mediated
bymitochondrial changes [43]. Interestingly, additional stim-
ulation using insulin may significantly reverse these addi-
tions, such that they remain responsive along the standard
pathways of metabolism. Arginine metabolism has also been
suggested to be involved in M1 control, while other metabo-
lites are probably also relevant to uncertain capacities [44].
In addition, as part of their phagocytotic capacity,
macrophages may also uptake large amounts of cholesterol
to become foam cells. Foam cells have been identified to
occur in a number of renal conditions, and some recent work
has focused on promoting cholesterol efflux to prevent foam
cell buildup, but it remains to be seen if foam cells should
truly be targeted or simply regarded as a marker [45]. In
addition, the nuclear receptors FXR, LXR, andPXRhave been
identified to have important function in regulation of M1,
particularly in the Kupffer cells of the liver and in resident
macrophage populations in the kidneys. Activation of the bile
acid receptor FXR has been shown to repress macrophage
function and infiltration capability in DN, partly by suppress-
ing the IFN𝛾 mediated activation of STAT1 [46]. However,
FXR activationmay not be wholly anti-inflammatory, with its
mechanistic control still not fully understood. LXR function
in macrophages has largely been explored in the context of
atherosclerosis, in which LXR activation has been reported
to induce efflux of cholesterol from macrophages [47]. LXR
activation also influences the activity of the transcription
factors IRF8 and Pu.1 [48].These effects have been confirmed
in DN, with LXR activation leading to the amelioration of the
condition [49].This amelioration might be highly dependent
on macrophage function, as the AP-1 and NF-𝜅B signaling
pathways have been shown to be important inDN, since those
pathways feature prominently inmacrophages. PXRmay also
influence macrophage sensitivity to cholesterol, although it
may play a more important role in regulating the metabolism
of the drugs being used to treat DN given its general role in
controlling drug responses [50]. At the same time, activation
of these nuclear receptors may also lead to the induction of
PPAR family members such as PPAR𝛼, which can then serve
to negatively regulate inflammation [51]. PPAR𝛼 has also
been shown to influence the self-renewal of erythrocyte pro-
genitors [52]. The balancing of the proinflammatory effects
metabolites may have and the anti-inflammatory effects of
their activated receptors remains to be clarified.
Overall, macrophages tend to trend towards M1 at the
onset of inflammation and then switch to M2 to promote
healing some time thereafter. The precise mechanisms that
induce such a switch are not understood, although damage
sensing, further cytokine stimulation, and autocrine regula-
tion have been proposed as possible reasons [53–55]. Changes
in the expression of surface markers such as from CD11b
to CD163 may be used to monitor these changes in part
but are not wholly sufficient given the persistent expression
of perceived M1 markers well after a change in cytokine
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production has been observed. A large and varied assortment
of compounds have attempted to target this transdifferen-
tiation process as a means for alleviating the inflammation
in DN and other autoimmune disorders, but none have
been extremely successful thus far, despite revealing some
interesting target options [56]. Many of these compounds
have focused on repressing the activity of M1 transcription
factors through selective inhibition, but it is not clear if the
transition is actually controlled along a specific pathway. The
precise order in which these changes occur is also not fully
known.
M2 macrophage differentiation has been one of the key
goals for immunology-based treatments for DN, due to the
protective effects M2 may induce. In particular, M2 are
responsible for the secretion of IL-10, a potent cytokine that
can act to suppress the activity of most proinflammatory cell
types. IL-10 function runs counter to that of TNF𝛼, helping
to shut down its efficacy, partly by disrupting the p38/MAPK
pathway [57]. IL-10 may also lead to the suppression of iNOS
activity via the induction ofHO-1 and consequent CO salvage
[58]. In addition, IL-10 mediated induction of a PI3K/AKT
pathway for cell survivalmay directly improvewound healing
despite otherwise hindering proliferation [59]. Polyamine
secretion from M2 may also encourage the resolution of
inflammation by influencing transcription programs in other
cells [60]. Curiously, M2 function is coordinated to a large
extent by IRF4, which is typically understood to be a prolifer-
ative and proinflammatory transcription factor across a wide
range of different cell types. The exact signal transduction
network in play within M2 macrophages that reverses that
typical functional pathway is unknown.
3. T Helper Cells
Thelper cells become relevant at the site of inflammation later
than APCs but still have an important functional role in reg-
ulating inflammation resolution or lack thereof. T helper cells
do not typically have as strong of a residency status as other
immune cells, but some tissue-specific markers have been
identified. Once activated, CD4+ T cells can organize many
of the hallmark signs of inflammation, such as widespread
recruitment and chemokine release [61]. Of particular inter-
est in DN is the fact that CD4+ T helpers have been shown
to engage in significant crosstalk with fibroblasts to influence
fibrosis [62]. As such, targeting against several of these subsets
has been shown to be useful in treating DN, particularlyTh17
and Th1 [63]. T helper cells can be conventionally split into
T effector or T regulatory phenotypes, with the proinflam-
matory Th1, Th2, Th17, Th9, and Th22 subsets forming the
CD4+ subset of the former. Each of these subtypes has the
capability of producing signature cytokines, although such
production is not necessarily exclusive. Lineage-defining
transcription factors may be highly expressed and critically
regulate the function of these subtypes, with dynamic inter-
play between them potentially contributing to the nature of
their polarization. The precise strength of TCR signaling at
the beginning of their activation has been shown to bias
future differentiation towards certain phenotypes [64, 65].
Different metabolites have been demonstrated to also have
variable impact across these different phenotypes, although
many of those differences remain undiscovered. CD4+ T
cells can also be highly plastic, adopting multiple phenotypes
either over time or even simultaneously [66]. As such, it is
useful to first consider all of the CD4+ cells in context before
examining the particular factors that a particular phenotype
may hold somewhat exclusively.
CD4+ T cell activation occurs along a multistep pathway,
with bona fide activation being somewhat ambiguous. The
energy need during this differentiation process, while notwell
studied, is likely to be quite high, given the clear disparity
in metabolic intake between differentiated T effector types
and näıve Th0 cells. During this differentiation process, cells
may be directly activated and subsequently polarized or
potentially undergo a “failed” activation and instead enter
into a state of anergy. The nature of CD4+ anergy is not
well known, with much of the current information on this
phenomenon having been gleaned from analogous study on
CD8+ T cells. Anergetic T cells are understood to have very
weak, if any, capability of sending further stimulation to other
cells, especially via cytokine production [67]. Several types
of viral infections are known to induce T cell anergy as a
means of escaping immune suppression, and TGF𝛽 signaling
is thought to be involved, but much remains to be clarified.
Intriguingly, TLR7 activation following damage sensing has
been suggested to induce this state of anergy, implying a
potential increase in the population of anergetic T cells in the
context of DN [68].
Following activation, T helpers can then pass through
a functional stage of variable duration before eventually
making a choice to become memory cells or otherwise
undergo exhaustion or apoptosis. CD4+ T helper memory
is thought to be critically regulated by TSLP, which may
induce the cells to adopt a lower metabolic profile [69].
More recently, a newer exhaustion phenomenon has been
uncovered, which has been treated as being distinct from
simple plastic transitions across different phenotypes [70].
CD4+ T cells are known to require significant autocrine
secretion of IL-2 (as well as lesser amounts of IL-5 and IL-
7) in order to maintain their viability and continue func-
tioning [71]. In some viral diseases however, T cell function
has been observed to fade over time, with IL-2 autocrine
signaling being suppressed [72, 73]. This suppression has
been correlated with the increased expression of the cell
surfacemarker PD-1 and the transcription factor Bcl6, among
others [74]. While some early speculation held that these
cells were in fact merely becoming Tfh-like, the observation
of other markers such as Tim-3 suggests otherwise [75].
OnceCD4+ cells begin to undergo exhaustion, they gradually
lose functions one at a time. Recently, several authors have
proposed that this type of exhaustion may also occur in cases
of chronic inflammation, where the continued activation and
function of CD4+ cellsmay eventually be suppressed through
some sort of internal transition. This type of exhaustion-
mediated transition has thus far been identified to occur
between Th17 and Treg phenotypes but may also occur
between other T effector types and T regulatory types [70].
This type of exhaustion is likely caused by some kind of
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damage sensing mechanism or perhaps the extreme buildup
of stress thatmay occur in chronic inflammation.Deprivation
of sufficient nutrients/metabolites may also contribute to
exhaustion occurring.
CD4+ T helper tolerance of glucose has been shown to
be an important factor in the pathogenesis of diabetes and
as such is also highly relevant to DN. In particular, Th17 and
Th1 cells have been identified as contributing factors. Th17
cells are a highly active T cell population classically activated
through the cytokines IL-6 and TGF-𝛽 or alternatively
activated into a pathogenic form via IL-1𝛽, IL-6, and IL-23. As
noted previously, these cytokines are often present in signifi-
cant concentrations in the local environment during inflam-
mation, with significant amounts of them being released by
epithelial cells, particularly by those under stress. Once Th17
cells receive signaling along either tract, a JAK/STATpathway
is activated, culminating in STAT3 activation of ROR𝛾t and
ensuing production of IL-17 [76]. Changes in the production
of IL-17 and in the expression of ROR𝛾t are understood to be
themost conclusive indicators of change inTh17 function, but
it is also possible that other changes may emerge even earlier.
Th17 function has been explored as a possible contributor to
worsening DN, but the actual strength of the connection is
unclear. Some studies have suggested that Th17 cells might
be uniquely upregulated in DN, although it is also possible
that the increase is simply a part of a general increase
in proinflammatory cytokines [63]. Th1 cells are a similar
proinflammatory subset that often responds in a similar
fashion to Th17 cells in the face of stimulus. By contrast, Th1
cells produce large amounts of IFN𝛾 and express the tran-
scription factor T-bet (Tbx21). Stimulated by the common
APC product IL-12p40, Th1 cells rely on STAT4 activation
at the end of a JAK/STAT pathway to function. Like other T
helper subtypes, Th1 are also influenced by BATF-driven and
IRF4-driven transcription networks [77]. Th1 cells have also
been shown to be likely candidates for upregulation in DN.
CD4+ T helpers may also respond differently to common
forms of oxidative stress common in DN. Th17 cells may
also be preferentially activated by the hypoxia environment
that can form in DN, although they are also susceptible to
inhibition by nitric oxide and other ROS stress [78]. In this
manner, they differ from other CD4+ T helpers which are
less responsive to NO or otherwise feed off of it to increase
inflammation, such as Th9 [79]. Unlike APCs, T helper
cells have significantly muted expression of classical DAMP
and PAMP receptors, such that they are not as likely to be
directly influenced by danger signals such as extracellular
DNA. Recent work has shown that human T helpers may
be inhibited via activation of TLR7 however, raising hope
that other direct influences may also be uncovered. APC
transduction of such signaling might occur at a rapid pace
in DN however, especially given the broad scale damage
that is present during accelerated remodeling. In addition,
T cells can directly receive signaling via other extracellular
metabolites, such as ATP [80]. Extracellular ATP may then
activate the AMPK pathway to increase inflammation by
upregulating metabolism [81]. While it is not intuitively
obvious that increases in metabolism must correlate with
an increase in inflammation, it is almost always the case, as
basic increases of metabolism can strongly impact cellular
activation [82].
Metabolic control of CD4+ T helpers has been the focus
of increased study in recent years, with many metabolic
products having been identified to bias cellular polarization.
For instance, succinate, an intermediate in the Krebs cycle,
has been shown to play an important role in modulating
Th17 activity [83]. Provision of excess amino acids has
also been shown to somewhat preferentially induce Th17
activation, while its opposite starvation selectively inhibits
the phenotype [84, 85]. Other metabolites, such as salt, have
also been shown to induce T effector activity, although it
is also possible that the change is primarily a result of an
increase in osmolality [86, 87]. Glucose can similarly lead to
the creation of phenotype bias [88]. Interestingly, in many of
these cases, the Th2 and Treg phenotypes are not affected,
for reasons not fully clear. One particularly striking example
of this phenomenon is the fact that BRD4 inhibition seems
to sharply limit Th1 and Th17 activity while leaving Th2 and
Treg populations at original levels, despite the fact that BRD4
is broadly expressed across CD4+ lineages and is a very
general factor critical for the assembly of the superelongation
complex for replication and transcription [89, 90]. It may also
be possible that CD4+ T helpers can respond differently to
the provision of nucleotides or other metabolites of different
classes. Regardless, this differing need for variousmetabolites
leads to a useful potential source for T helper targeting or
at the very least cautions against the use of some methods
for treatment. For instance, the inhibition of Th17 cells has
been a longstanding goal inmany conditions besidesDN, and
one of the prime means for achieving this has been through
the treatment of broad-acting corticosteroids. Unfortunately
however, recent research suggests thatTh17 cells may actually
be able to more effectively respond to corticosteroid stress
than some other subsets and actually survive such inhibition
over the short term [91]. As such, it is important to observe
that these metabolic differences can only be targeted in cases
where one cell type expresses and requires a metabolite that
other polarization states do not also need.
4. Tubular Cells
While not immune cells, tubular cells in the kidneymay serve
to propagatemany of the immune signals present inDN, both
through direct cytokines and through metabolites. After all,
tubular cells handle filtered glucose and other metabolites,
while also transporting electrolytes and water. Although
currently there are debates about whether or not the primary
role of tubular cells is acting in parallel with glomerular cells
in the pathogenesis of DN, it is a well received fact that
functional dysregulation in the tubules and cell injury are
main contributors to DN [92]. As noted previously, one of the
early pathologic changes in DN is tubular cell hypertrophy,
followed by increased thickness of tubular basement mem-
branes. These changes affect the composition of the extra-
cellular matrix and drive feedback for further changes [93].
Subsequently, tubular atrophy, atubular glomeruli, extensive
immune cell infiltration, and fibrosis develop and progress
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[94]. Multiple factors including hypermetabolism, excessive
free radicals, and chronic inflammation have been implicated
in DN tubulointerstitial lesions. Naturally, work load in
tubular cells in diabetes is greatly elevated as a result of
hyperfiltration, along with accumulated high glucose and
related metabolites. Accordingly, energy generation and con-
sumption are increased to meet the functional need, leading
to a state of hypermetabolism that provokes cell stress and
free radical overgeneration [95]. Moreover, nonenzymatic
interactions between high glucose pressure and proteins
promote the generation of carbonyls in the process, as well as
advanced glycation end products which provoke free radical
synthesis [96]. This cycle may also cause positive feedback in
the absence of a functional response to insulin [97]. Tubular
cells may also directly produce TGF𝛽 in response to glucose
to directly modulate immune function [98].
Free radicals are widely recognized to be critical for DN
pathology. Free radicals may directly damage cell structures
and modify cellular proteins and DNA, resulting in cell
stress and injury, which may subsequently activate DCs
and macrophages to initiate a pattern of damage associated
sterile inflammation [10]. Additionally, free radicals may
oxidize nitric oxide (NO) to decrease NO availability and
cause vasoconstriction, leading to decreased tubular blood
supply and hypoxia. Hypoxia suppresses prolyl hydroxylase
domain proteins and activates oxygen sensing transcription
factor hypoxia inducible factor (HIF-1𝛼). It is noted that
free radicals can also increase HIF-1𝛼 transcription and
function by directly activating the HIF-1𝛼 promoter and
regulating hydroxylase function of the asparaginyl hydrox-
ylase [99]. Indeed, the levels of HIF have been noted to
increase in the tubular and interstitial cells of DN, and
the suppression of HIF has been shown to ameliorate DN
[100]. One of important functions of HIF is to switch cell
metabolism from oxidative phosphorylation to glycolysis to
increase cell survival under hypoxic condition. However,
this metabolic shift also causes the changes in immune cell
phenotypes that favor inflammation. HIF-family proteins
increase macrophage aggregation, invasion, and mobility
and are intimately involved in macrophage polarization. For
instance, macrophages lacking HIF-2𝛼 cannot be stimulated
via LPS to generateM1 inflammatory responses.The function
of HIF in DCs is less clear. Hypoxia induces the production
of proinflammatory cytokines TNF𝛼 and IL-1𝛽 by DCs.
On the other hand, DCs cultured under hypoxia have less
costimulatory molecules and maturation markers and show
decreased migration in response to C-C chemokine receptor
type 7 ligands [101].
Since the process of T cell activation and differentiation is
tightly associated with metabolic switch, it is not unexpected
to find a role for HIF in T cell activation and differentiation.
Th1,Th2, andTh17 cells exhibited increased glycolysis and less
oxidative phosphorylation compared to T regulatory cells,
which show a greater reliance on lipid oxidation and oxidative
phosphorylation [102]. Th17 has high levels of HIF-1𝛼 and
deletion of HIF-1𝛼 in T cells inhibits Th17 differentiation
in vitro and in experimental autoimmune encephalomyelitis
[103]. In contrast, hypoxia and deletion of HIF ubiquitination
ligaseVHLboth promote stabilization ofHIF-1𝛼 and enhance
generation of Th17 CD4+ cells. The generation of Treg is
usually opposite to the induction of Th17 CD4+ cells. Thus,
enhanced Treg cell differentiation was observed in the case of
HIF-1𝛼 deletion, a condition not favoring Th17 cells lineage
differentiation [104]. One possible molecular mechanism for
HIF attenuation of Treg cell development is direct binding
and targeting of the Treg lineage-defining transcription factor
Foxp3 for degradation [105]. HIF-1𝛼 can also affect metabolic
adaptations in CD8+ T cells and control expression of many
molecules associated with effector function and migration
[106]. HIF-1𝛽-deficient T cells show diminished expression
of effector molecules. Overall, HIF activation by hypoxic
microenvironment as well as free radicals in tubulointerstitial
area favors inflammation via modulation of immune cells.
The levels of HIF are also elevated in tubular cells in DN.
It is unknown if HIF also directly promotes the inflammation
in tubular cells. However, since the preferred metabolic fuels
for tubular cells are not glucose, the act of HIF on these cells
may differ. Nevertheless, phenotypic alteration of tubular
cells to proinflammatory has been observed in DN. This
may contribute directly to local inflammation. Both high
glucose and advanced glycation end products can activate
NF-𝜅B and inflammasome and upregulate MCP-1 and
VCAM-1 in tubular cells, while also promoting further ECM
modifications [107]. Large amounts of albuminuria have
also been implicated in the proinflammatory phenotype of
tubular cells [108].
Finally, apart from genetic susceptibility, DN takes about
10–20 years to develop as the result of multiple vicious inter-
plays among dysregulated metabolism, cell stress and injury,
chronic inflammation, and epigenetic changes. Although we
have gained some knowledge about the pathogenesis of DN
and have developed some treatment in recent years, at present
we are still unable to prevent disease progression to diabetic
renal failure. As such, it is critical to understand the details of
metabolic abnormalities, the pros and cons of HIF activation,
and the keys to block chronic inflammation in order to enable
more effective treatment of DN.
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